






- 1 University of Cambridge & Royal Papworth Hospital - Cambridge (UK)
- 2 Royal Statistical Society London (UK)
- 3 PHA Europe Vienna (Austria)
- 4 PHA USA Washington (USA)
- 5 Imperial College Healthcare NHS Trust -London (UK) 6 Europejskie Centrum Zdrowia Otwock -
- Otwock (Poland)
- 7 Great Ormond Street Hospital London (UK) 8 ERN-LUNG - Frankfurt (Germany)
- 9 Royal Society, Entrepreneur in Residence, University of Bath & iOWNA Ltd - Bath &
- London (UK) 10 Pulmonary Vascular Research Institute -
- London (UK) 11 Pulmonary Hypertension Associations - global network



- PHAEUR PE Jenna Lowe OWNA. Great Ormond Street Hospital for Children

The authors have no real or perceived conflicts of interest that relate to this presentation.

Pulmonary Hypertension Global Patient Survey: an overview and results PHGP2 J.Newman¹, S.Munagala², M.Fay, G.Fischer³, M.Granato⁴, L.Howard⁵, M.Kurzyna⁶, L.Macdonald⁷, G.Meszaros⁸, E.Otter³, M.Stone⁹, K.Bunclark¹, M.Toshner¹, M.Tschida³, PVRI IDDI Patient Engagement & Empowerment Workstream¹⁰, PH GPS Consortium¹¹, J.Pepke-Zaba¹ Methods 🎝 • Survey drafted via an iterative consensus-building process by a **multi-disciplinary panel** of collaborators: • patients, physicians, nurses, researchers, industry partners advocates from Pulmonary Hypertension Associations (PHAs)



Results – example data regarding clinical trial participation

Conclusions 😭

• The scale and depth of patient-generated data in PH GPS helps to fill the knowledge gap regarding patients' perspectives across all PH groups and including paediatrics. • For example, only a minority (19%) of patients in this global contemporary survey have participated in a PH clinical research trial, but the majority (72%) would engage if invited. • The results from the survey will inform international clinical guidelines, research priorities and health policy, to improve care and outcomes of patients globally.

With thanks to all patients, relatives and caregivers who have participated, and our many collaborators including those in the PVRI IDDI Patient Empowerment and Engagement Group

Unsure

12.1%

- David Badesch, University of Colorado • Diana Haberle, Janssen
- Gabi Lowe, Jenna Lowe Trust/Patient Advocate
- Gerry Fischer, PHA Europe
- Hall Skaara, PHA Europe

- Helen Whitford, Alfred University Hospital, Melbourne
 Jeremy Durand, PHA Canada
- HuangHuan, Aixike/Patient Rep, China • Iain Armstrong, PHA UK
- Jamie Myrah, PHA Canada
- Jamie Strachan, The Dinosaur Trust

- Themes included time to diagnosis, treatment, quality of life, research participation and digital health.
- Online survey with over **100 questions** inclusive of PH Groups 1 to 5 through 3 parallel responder streams:
 - adult patients
 - carers/relatives of adult patients
 - parents/guardians of paediatric patients
- Translated, beta-tested and rolled out in **24 languages** from October 2023 for 2 months.
- **Disseminated by PHAs** via traditional and social media.
- Mixed-methods analysis quantitative descriptive statistics (by region; by PH group) and qualitative thematic analysis.

This varies *5.9% in Africa to Have you ever taken part in a clinical research trial across regions 25.1% in Central/East Europe. and PH groups ** (which involved research into a drug or device for PH)? **9.2% in Group 3 to n=3335 adult PH patients 23.5% in Group 1. respons 7.5% Yes 19.0% What was your overall experience of the trial like? n=635 No opinion orno espons No 27.2% Good 73.1% 16.2% Would you participate n=68 n=464 again in a clinical trial?



Yes 57.4%

- Luccilla Piccari, Hospital del Mar, Barcelona
- Luke Howard, Imperial College London
- Maurice Beghetti, Children's University Hospital, Switzerland
- Pisana Ferrari, Alliance for PH

No 26.5%

- Mumbai
- Shahin Moledina, GOSH, London Shaun Clayton, PHA UK




7-11 September | Vienna, Austria



ERS Virtual Platform - PA2501

Results – other highlights 💒 57% 34% of adult of adults with Group 1 patients **IPAH/HPAH** were **diagnosed** have had genetic within 12 months testing \mathbb{M} 21% 91% of adult patients of all adult PH have completed a patients report at **Patient Reported** least some sleep **Outcome Measure** disturbance ÷××× 47% 74% of all adult PH of adult patients report side effects patients have had from PH meds in negatively impacted last 6 months employment To make a data request and for more information, please go to: https://pvri.link/phgps

Or email: joseph.newman@nhs.net



Prashant Bobhate, Kokilaben Dhirubhai Ambani,

• Sylvia Nikko, Bayer

- Tess Jewson, Patient Representative
- Virginie Gressin, Janssen
- Wendy Gin-Sing, Nurse Consultant